Argent Biopharma Ltd (ASX: RGT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Argent Biopharma Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $4.87 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 86.94 million
Earnings per share -0.312
Dividend per share N/A
Year To Date Return -18.57%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Argent Biopharma Ltd (ASX: RGT)
    Latest News

    a woman
    ⏸️ Investing

    Why these 4 ASX shares started the week with a bang

    The Myer Holdings Ltd (ASX:MYR) share price is one of four starting the week with a bang. Here's why...

    Read more »

    a woman
    ⏸️ Investing

    Why cannabis company MGC Pharmaceuticals Ltd is up 14% today

    The MGC Pharmaceuticals Ltd (ASX:MXC) share price has been a big mover during trade on Monday. Here's why...

    Read more »

    a woman
    ⏸️ Investing

    Cannabis company MGC Pharmaceuticals Ltd storms higher

    The MGC Pharmaceuticals Ltd (ASX:MXC) share price has been a big mover on Wednesday. Here's why...

    Read more »

    a woman
    ⏸️ Investing

    Medicinal cannabis shares crash lower

    The Auscann Group Holdings Ltd (ASX:AC8) share price is one of a number sinking lower in the medicinal cannabis industry…

    Read more »

    a woman
    ⏸️ Investing

    These 3 ASX shares just raced to 52-week highs

    The WiseTech Global Ltd (ASX:WTC) share price is one of three hitting a 52-week high this week…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares are ending the week with a bang

    The Kogan.com Ltd (ASX:KGN) share price is one of four ending the week with a bang. Here's why…

    Read more »

    a woman
    ⏸️ Investing

    Why pot stock MGC Pharmaceuticals surged higher today

    The MGC Pharmaceuticals Ltd (ASX:MXC) share price has surged higher on Thursday. Here's why…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares have started the week higher

    The Bellamy's Australia Ltd (ASX:BAL) share price is one of four starting the week with a move higher. Here's what…

    Read more »

    a woman
    ⏸️ Investing

    Why the pot stocks crashed lower

    The Cann Group Ltd (ASX:CAN) share price was one of seven in the pot stock industry sinking lower…

    Read more »

    a woman
    ⏸️ Investing

    How Queensland Bauxite Ltd plans to cash in on cannabis

    Queensland Bauxite Ltd (ASX:QBL) seems to be more about cannabis than mining. And it looks to be paying off.

    Read more »

    a woman
    ⏸️ Investing

    Why these 3 ASX shares are at 52-week highs

    The BWX Ltd (ASX:BWX) share price is one of three hitting a 52-week high on Monday. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares are ending the week with strong gains

    The Auscann Group Holdings Ltd (ASX:AC8) share price is one of four ending the week with strong gains. Here’s why…

    Read more »

    RGT ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Argent Biopharma Ltd

    MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. Its Endocannabinoid system covers all cells and nerves; it is the messenger of information flowing between immune system and the central nervous system. The company was founded by Nativ Segev on October 21, 2005 and is headquartered in Perth, Australia.

    RGT Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    27 Feb 2026 $0.06 $0.00 0.00% 132,305 $0.06 $0.06 $0.05
    26 Feb 2026 $0.06 $0.00 0.00% 54,472 $0.06 $0.06 $0.06
    25 Feb 2026 $0.06 $0.00 0.00% 47,698 $0.06 $0.06 $0.06
    24 Feb 2026 $0.06 $-0.01 -16.13% 68,059 $0.06 $0.06 $0.05
    23 Feb 2026 $0.06 $0.01 19.61% 117,151 $0.05 $0.06 $0.05
    20 Feb 2026 $0.05 $0.00 0.00% 27,178 $0.05 $0.05 $0.05
    19 Feb 2026 $0.05 $0.00 0.00% 281,626 $0.06 $0.06 $0.05
    18 Feb 2026 $0.05 $0.00 0.00% 268,065 $0.06 $0.06 $0.05
    17 Feb 2026 $0.06 $0.00 0.00% 44,979 $0.06 $0.06 $0.06
    16 Feb 2026 $0.06 $0.00 0.00% 15,500 $0.06 $0.06 $0.06
    13 Feb 2026 $0.06 $0.00 0.00% 11,240 $0.06 $0.06 $0.06
    12 Feb 2026 $0.06 $0.00 0.00% 10,000 $0.06 $0.06 $0.06
    11 Feb 2026 $0.06 $0.00 0.00% 52,639 $0.06 $0.06 $0.06
    10 Feb 2026 $0.06 $0.00 0.00% 51,570 $0.05 $0.06 $0.05
    09 Feb 2026 $0.05 $0.00 0.00% 14,699 $0.05 $0.05 $0.05
    06 Feb 2026 $0.05 $0.00 0.00% 31,771 $0.05 $0.05 $0.05
    05 Feb 2026 $0.05 $0.00 0.00% 307,070 $0.06 $0.06 $0.05
    04 Feb 2026 $0.05 $0.00 0.00% 29,339 $0.06 $0.06 $0.05
    03 Feb 2026 $0.05 $0.00 0.00% 77,708 $0.05 $0.06 $0.05
    02 Feb 2026 $0.05 $0.00 0.00% 54,710 $0.06 $0.06 $0.05
    30 Jan 2026 $0.06 $0.00 0.00% 195,074 $0.06 $0.06 $0.06

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Daniel Robinson Non-Executive Director Dec 2023
    Mr Robinson has over 20 years' experience in multiple corporate roles across stockbroking, corporate advisory, investor relations and governance. He is an experienced Company Secretary and Director of both private and listed companies.
    Mr Roby Reuven Zomer Chief Executive OfficerManaging Director Feb 2016
    Mr Zomer has experience in the biopharmaceutical and biotech industries. As the CEO of the company, Roby has demonstrated has driven strategic growth, managed financial operations, and ensured compliance with industry-specific standards. He also served as the Chairman of the Board for Graft Polymer, overseeing the implementation of advanced polymer solutions in the Biotech, Automotive and Recycling sectors. Roby's entrepreneurial background includes founding and leading Green City Urban Recycling, a pioneering Israeli company focused on biofuel production. His work in this field contributed to national energy independence initiatives and led to the company's acquisition by Rafael Advanced Defense Systems. With an industrial engineering and management foundation, Roby Zomer brings a blend of technical and strategic skills to his professional endeavors.
    Mr Gary Hermon Non-Executive Director Mar 2025
    Mr Hermon has over 30 years of experience in telecommunications, electrical systems, and infrastructure rollout. Throughout his career, he has managed projects for clients, including Hewlett-Packard, the Victorian Government, BP, and ExxonMobil. At Haumea Pty Ltd, Gary focuses on cable data infrastructure, CCTV systems, and communications networks, ensuring efficient project delivery.
    Mr Rowan Harland Company Secretary Mar 2023
    -
    Rowan Harland Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    A2 Invest Llc 11,250,000 15.59%
    Oak Capital Partners Llc 10,870,718 15.06%
    HSBC Custody Nominees (Australia) Limited 5,655,176 7.83%
    Group Capital Llc 3,913,812 5.42%
    Citicorp Nominees Pty Limited 3,911,828 5.42%
    David Safren 3,405,016 4.72%
    Shlomie Bierman 2,230,874 3.09%
    Isamar Margareten 1,956,906 2.71%
    Yaakov Safren 1,643,802 2.28%
    Jacob Goldstein 1,623,072 2.25%
    Yoram Drucker 1,604,664 2.22%
    Yosef Safren 1,565,526 2.17%
    Shalom Safren 1,448,112 2.01%
    Mr Shachar Shimony 1,371,500 1.90%
    Mrs Yifat Steuer 1,117,194 1.55%
    Mercer Street Global Opportunity Fund Llc 836,000 1.16%
    Eliron Yaron 750,000 1.04%
    A1 Invest Llc 625,000 0.87%
    BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> 567,768 0.79%
    Joseph Schwartz 547,934 0.76%

    Profile

    since

    Note